Associate Professor Jonathon Arnold

Associate Professor
Pharmacology, School of Medical Sciences
Bosch Institute

Telephone +61 2 9036 5361
Fax +61 2 9351 7328

Map

Biographical details

Jonathon Arnold is an Associate Professor at the University of Sydney and has over 15 years experience in behavioural neuroscience and pharmacology. He has published 42 manuscripts in peer-reviewed journals and has received over 1000 career citations, h-index = 19). He completed his PhD on the neural and behavioural effects of cannabinoids (cannabis-like drugs) under Professor Iain McGregor at the University of Sydney in 2001. During his PhD Dr Arnold became fascinated by how genetic disposition influences the neurobehavioural actions of cannabinoids - understanding which genes affect cannabinoid action might help explain why certain individuals are more prone to mental disorders such as addiction or schizophrenia.

A/Prof Arnold's research has attracted national and international funding. In 2005 he took sabbatical leave at the Cajal Institute in Madrid, one of the world's premier neuroscience institutes. He has an ongoing collaboration with Prof Jacques Micheau, University of Bordeaux, France that has yielded 4 publications. He has published invited reviews in special cannabinoid editions of Current Pharmaceutical Design, Pharmacology, Biochemistry and Behavior and the British Journal of Pharmacology. In 2009 he reported from NHMRC-funded research that diet-induced lipolysis causes fat-stored THC to flood back into the blood (the phenomenon we termed cannabinoid re-intoxication, published in the British Journal of Pharmacology). This finding attracted national and international media attention including coverage in the New Scientist, Cosmos, and the Sun-Herald. His work on Nrg1-cannabinoid interactions has also generated much interest and he has given 6 invited presentations at both national and international conferences on this topic in the last 5 years.

Dr Arnold has reviewed grants for the National Health and Medical Research Council,Australian Research Council, the Marsden Fund (New Zealand) and the Michael Smith Foundation for Health Research (Canada). He also reviews original research manuscripts for various international journals including Schizophrenia Bulletin,Biological Psychiatry, Neuropsychopharmacology, Journal of Pharmacology and Experimental Therapeutics, PLoS ONE and The British Journal of Pharmacology. He serves on the Editorial Board of Current Neuropharmacology andThe World Journal of Pharmacology. He is the primary supervisor of 6 PhD students and has supervised 3 PhD students, 1 Masters and 12 Honours students to completion (10 awarded a 1st class grading, 5 retained for PhD studies). In 2011 he received the Excellence in Research Higher Degree Supervision Award from the Sydney Medical School.

Research interests

A/Prof Arnold has isolated genes that modulate the neurobehavioural effects of cannabinoids. His research has focussed on ABC transporter genes that encode drug efflux pumps found at the blood brain barrier. These might regulate cannabinoid brain uptake by transporting cannabinoid drugs from brain tissue back into the peripheral blood supply. His group was the first to show cannabinoids modulate activity and expression ofABCB1in 2006 (published inBiochemical Pharmacology) andABCG2in 2007 (published in theBritish Journal of Pharmacology). In recognition of this research A/Prof Arnold received a Young Investigator Award from the US-basedBrain and Behavior Research Foundation(formerly known as NARSAD). The other major arm of his research demonstrated that the schizophrenia susceptibility gene neuregulin 1 (Nrg1) modulates the neuropharmacological actions of cannabinoids. The seminal manuscripts on this topic published in 2007 inPsychopharmacologyandNeurosciencehave received collectively over 100 citations. His research has influenced human genomic research in psychiatry, for example, a recently accepted publication inBiological Psychiatryfrom researchers at Yale University reported thatNRG1increased the risk of developing cannabis dependence. His recent publication in theInternational Journal of Neuropsychopharmacologyis the first to showNrg1is involved in the development of cannabinoid tolerance. In 2009 Dr Arnold established a Neurobehavioural Laboratory at the Brain and Mind Research Institute (BMRI) in collaboration with Professor Max Bennett.

International links

France

(University of Bordeaux) Collaboration with Prof Jacques Micheau on the effects on cannabinoids on cognition.

Iran

(Babol Medical Science University) Collaboration with Dr Ibrahim Zabihi

Selected grants

2014

  • Randomised control trial of exercise for the management of cannabis withdrawal in adult humans; Lintzeris N, McGregor I, Rooney K, Allsop D, Arnold J; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Stereotaxic frame; Arnold J, Christie M, Collins M, Sawatari A, Leamey C, Stone J, van Nieuwenhuijzen P, Chan-Ling T, Balle T; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2013

  • Mouse behavioural phenotyping battery; Hunt N, Christie M, McGregor I, Kassiou M, Collins M, Stone J, Arnold J, Sawatari A, Mitrofanis J, Camp A; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Leica PowerMosaic plus microsope upgrade for flexible, high-resolution slide scanning; Gamble J, McCaughan G, Feng C, Fazekas B, Weninger W, Shackel N, Bertolino P, Lovelace M, Saunders B, Armati P, Pollard J, Pai S, Arnold J, Triccas J, Goldsbury C, Bailey C, Mrass P, Rasko J, Biro M; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • ABC transporters and cannabis-induced psychosis; Arnold J; DVC Research/Bridging Support Grant.

2012

  • A flexible high throughput analytical system for psychopharmacology and drug discovery; McGregor I, Simpson S, Shannon Weickert C, Kassiou M, Copeland J, Solowij N, Codd R, Arnold J, Karl T, Long L; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).

2011

  • Neuregulini and stress interact to promote schizophrenia; Arnold J; DVC Research/Bridging Support Grant.

2010

  • An animal model of gene-environment interaction in Schizophrenia: equipment purchase; Arnold J; Schizophrenia Research Institute/Research Support.
  • Role of ABC transporters in resistance to antipsychotic therapy and cannabinoid antipsychotic drug interactions; Arnold J; Brain and Behavior Research Foundation/Research Support.

2009

  • Atypical antipsychotic-induced weight gain and insulin insensitivity: a role for macrophage infiltration in adipose tissue; Arnold J; Schizophrenia Research Institute/Research Support.
  • A new Laser Microdissection Microscope with a unique pressure catapulting technique allows isolation of pure samples for subsequent downstream molecular analyses; Halliday G, Morris B, Mason R, Murphy C, Bishop A, Leamey C, Joshua D, Lee C, Iland H, Pamphlett R, Richardson D, King N, Hunt N, Arnold J, Morris M, Protti D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
  • Motion Menura multimodal mouse testing apparatus (MMTA): (Turnkey system comprising 6 testing chambers with associated control and tracking software).; Kemp A, Hermens D, McGregor I, Einfeld S, Kassiou M, Arnold J, Hunt G; National Health and Medical Research Council (NHMRC)/Equipment Grants.

2008

  • The role of cannabis in an Nrg1 animal model of genetic vulnerability to schizophrenia; Arnold J; Schizophrenia Research Institute/Research Support.

2007

  • 12th biennial meeting of the european behavioural pharmacology society - Germany September 2007; Arnold J; Ian Potter Foundation/Grants & Travel Grants.

2006

  • Cannabis re-intoxication: the causes and consequences of THC release from fat stores into blood; McGregor I, Arnold J; National Health and Medical Research Council (NHMRC)/Project Grants.
  • An Animal Model Of Genetic Vulnerability To Cannabis-Induced Psychosis; Arnold J; Clive & Vera Ramaciotti Foundation/General Grants.

2005

  • Flashback: the release of THC from fat stores as a result of food deprivation or stress; McGregor I, Arnold J; University of Sydney/Research & Development.

2004

  • Cannabinoids as anti-cancer agents:studies evaluating cytotoxic and multidrug resistance(MDR)reversal actions; Arnold J; University of Sydney/Cancer Research Fund.

2002

  • Cannabinoids as agents that reverse resistance to chemotherapy; Arnold J; DVC Research/Research and Development Scheme: Newly Appointed Staff (NAS).

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Wong, A., Keats, K., Rooney, K., Hicks, C., Allsop, D., Arnold, J., McGregor, I. (2014). Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences. Psychopharmacology, online. [More Information]
  • Swift, W., Wong, A., Li, K., Arnold, J., McGregor, I. (2013). Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile. PLoS One, 8(7), 1-9. [More Information]
  • Wong, A., Montebello, M., Norberg, M., Rooney, K., Lintzeris, N., Bruno, R., Booth, J., Arnold, J., McGregor, I. (2013). Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence, 133(2), 763-767. [More Information]
  • Spencer, J., Chohan, T., Karl, T., Arnold, J. (2013). Female neuregulin 1 heterozygous mice require repeated exposure to Δ9-tetrahydrocannabinol to alter sensorimotor gating function. Pharmacopsychiatry, 46(7), 286-291. [More Information]
  • Spencer, J., Darbyshire, K., Boucher, A., Kashem, M., Long, L., McGregor, I., Karl, T., Arnold, J. (2013). Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Frontiers in Cellular Neuroscience, 7, 1-13. [More Information]
  • Kassem, M., Lagopoulos, J., Stait-Gardner, T., Price, W., Chohan, T., Arnold, J., Hatton, S., Bennett, M. (2013). Stress-Induced Grey Matter Loss Determined by MRI Is Primarily Due to Loss of Dendrites and Their Synapses. Molecular Neurobiology, 47(2), 645-661. [More Information]
  • Long, L., Chesworth, R., Huang, X., McGregor, I., Arnold, J., Karl, T. (2013). Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. International Journal of Neuropsychopharmacology, 16(1), 163-175. [More Information]
  • Karl, T., Arnold, J. (2013). What does a mouse tell us about neuregulin 1-cannabis interactions? Frontiers in Cellular Neuroscience, 7, 1-4. [More Information]
  • Spencer, J., Darbyshire, K., Boucher, A., Arnold, J. (2012). Adolescent neuregulin 1 heterozygous mice display enhanced behavioral sensitivity to methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 39(2), 376-381. [More Information]
  • Arnold, J., Hone, P., Holland, M., Allen, J. (2012). CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacological Reports, 64(3), 751-757. [More Information]
  • Long, L., Chesworth, R., Huang, X., Wong, A., Spiro, A., McGregor, I., Arnold, J., Karl, T. (2012). Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. PLoS One, 7(4), 1-11. [More Information]
  • Spiro, A., Wong, A., Boucher, A., Arnold, J. (2012). Enhanced Brain Disposition and Effects of triangle 9-Tetrahydrocannabinol in P-Glycoprotein and Breast Cancer Resistance Protein Knockout Mice. PLoS One, 7(4), 1-6. [More Information]
  • Wong, A., Gunasekaran, N., Hancock, D., Denyer, G., Meng, L., Radford, J., McGregor, I., Arnold, J. (2012). The major plant-derived cannabinoid 9-tetrahydrocannabinol promotes hypertrophy and macrophage infiltration in adipose tissue. Hormone And Metabolic Research, 44(2), 105-113. [More Information]
  • Chesworth, R., Yulyaningsih, E., Cappas, E., Arnold, J., Salis, A., Karl, T. (2012). The response of neuregulin 1 mutant mice to acute restraint stress. Neuroscience Letters, 515(1), 82-86. [More Information]
  • Karl, T., Cheng, D., Garner, B., Arnold, J. (2012). The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opinion on Therapeutic Targets, 16(4), 407-420. [More Information]
  • Arnold, J., Boucher, A., Karl, T. (2012). The Yin and Yang of Cannabis-induced Psychosis: the Actions of (D)(9)-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia. Current Pharmaceutical Design, 18(32), 5113-5130. [More Information]
  • Bowen, M., Carson, D., Spiro, A., Arnold, J., McGregor, I. (2011). Adolescent Oxytocin Exposure Causes Persistent Reductions in Anxiety and Alcohol Consumption and Enhances Sociability in Rats. PLoS One, 6(11), 1 (e27237)-11. [More Information]
  • Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L., Huang, X., Arnold, J., McGregor, I., et al (2011). Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology, 218(2), 443-457. [More Information]
  • Ferguson (Sokolic), L., Long, L., Hunt, G., Arnold, J., McGregor, I. (2011). Disruptive effects of the prototypical cannabinoid Delta9-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats. Behavioural Pharmacology, 22(3), 191-202. [More Information]
  • Boucher, A., Arnold, J., Hunt, G., Spiro, A., Spencer, J., Brown, C., McGregor, I., Bennett, M., Kassiou, M. (2011). Resilience and Reduced C-FOS Expression in P2X7 Receptor Knockout Mice Exposed to Repeated Forced Swim Test. Neuroscience, 189, 170-177. [More Information]
  • Boucher, A., Hunt, G., Micheau, J., Huang, X., McGregor, I., Karl, T., Arnold, J. (2011). The schizophrenia-susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology, 14(5), 631-643. [More Information]
  • Long, L., Chesworth, R., Arnold, J., Karl, T. (2010). A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology, 211(3), 277-289. [More Information]
  • Arnold, J., Dielenberg, R., McGregor, I. (2010). Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: Strain differences in drug-induced anxiety. Life Sciences, 87(17-18), 572-578. [More Information]
  • van Nieuwenhuijzen, P., Long, L., Hunt, G., Arnold, J., McGregor, I. (2010). Residual social, memory and oxytocin-related changes in rats following repeated exposure to gamma-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Psychopharmacology, 212(4), 663-674. [More Information]
  • Carson, D., Hunt, G., Guastella, A., Barber, L., Cornish, J., Arnold, J., Boucher, A., McGregor, I. (2010). Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. Addiction Biology, 15(4), 448-463. [More Information]
  • Boucher, A., Hunt, G., Micheau, J., Huang, X., McGregor, I., Karl, T., Arnold, J. (2010). The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology, 14(5), 631-643. [More Information]
  • Long, L., Chesworth, R., Huang, X., McGregor, I., Arnold, J., Karl, T. (2009). A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. International Journal of Neuropsychopharmacology, 13 (2010)(7), 861-876. [More Information]
  • Boucher, A., Vivier, L., Metna-Laurent, M., Brayda-Bruno, L., Mons, N., Arnold, J., Micheau, J. (2009). Chronic treatment with [DELTA]9-tetrahydrocannabinol impairs spatial memory and reduces zif268 expression in the mouse forebrain. Behavioural Pharmacology, 20(1), 45-55. [More Information]
  • Gunasekaran, N., Long, L., Dawson, B., Hansen, G., Richardson, D., Li, K., Arnold, J., McGregor, I. (2009). Reintoxication: the release of fat-stored delta-9-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. British Journal of Pharmacology, 158(5), 1330-1337. [More Information]
  • Holland, M., Allen, J., Arnold, J. (2008). Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). European Journal of Pharmacology, 591, 128-131. [More Information]
  • Quinn, H., Matsumoto, I., Callaghan, P., Long, L., Arnold, J., Gunasekaran, N., Thompson, M., Dawson, B., Mallet, P., Kashem, M., Matsuda-Matsumoto, H., Iwazaki, T., McGregor, I. (2007). Adolescent rats find repeated delta-9-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology, 33 (epub ahead of print Jun 20), 1-14. [More Information]
  • McGregor, I., Arnold, J. (2007). Cannabis reward: biased towards the fairer sex? British Journal of Pharmacology, 152(5), 562-564. [More Information]
  • Boucher, A., Arnold, J., Duffy, L., Schofield, P., Micheau, J., Karl, T. (2007). Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Δ9-tetrahydrocannabinol. Psychopharmacology, 192(3), 325-336. [More Information]
  • Boucher, A., Hunt, G., Karl, T., Micheau, J., McGregor, I., Arnold, J. (2007). Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience, 149(4), 861-870. [More Information]
  • Holland, M., Lau, D., Allen, J., Arnold, J. (2007). The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. British Journal of Pharmacology, 152(5), 815-824. [More Information]
  • Karl, T., Duffy, L., Boucher, A., Arnold, J., Schofield, P. (2006). Genetic animal models for neuregulin 1 – valuable tools for schizophrenia research? Australian and New Zealand Journal of Psychiatry, 40(8, Supplement 2, Point No: O16), A115-A115.
  • Holland, M., Panetta, J., Hoskins, J., Bebawy, M., Roufogalis, B., Allen, J., Arnold, J. (2006). The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochemical Pharmacology, 71(8), 1146-1154. [More Information]
  • Morley, K., Arnold, J., McGregor, I. (2005). Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29(5), 648-657. [More Information]
  • Arnold, J. (2005). The role of endocannabinoid transmission in cocaine addiction. Pharmacology, Biochemistry and Behavior, 81(2), 396-406. [More Information]
  • Arnold, J., Hunt, G., McGregor, I. (2001). Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rat. Life Sciences, 70, 97-108.
  • Arnold, J., Topple, A., Hunt, G., McGregor, I., Mallet, P. (2001). The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Research, 921, 240-255.

Conferences

  • Holland, M., Allen, J., Bebawy, M., Roufogalis, B., Arnold, J. (2005). Cannabinoid Modulation of P-Glycoprtein Efflux Activity and Expression (Netherlands). Interantional association for cannabis as medicine conference, The Netherlands: Australian Society of Clinical and experimental Pharmacologists and Toxicologista.
  • Arnold, J., Holland, M., Bebawy, M., Roufogalis, B., Allen, J. (2005). Cannabinoid Modulation of P-Glycoprtein Efflux Activity and Expression (Spain). SOCIEDAD ESPANOLA DE INVESTIGACION SOBRE CANNABINOIDES, Barcelona: Australian Society of Clinical and experimental Pharmacologists and Toxicologista.

2014

  • Wong, A., Keats, K., Rooney, K., Hicks, C., Allsop, D., Arnold, J., McGregor, I. (2014). Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences. Psychopharmacology, online. [More Information]

2013

  • Swift, W., Wong, A., Li, K., Arnold, J., McGregor, I. (2013). Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile. PLoS One, 8(7), 1-9. [More Information]
  • Wong, A., Montebello, M., Norberg, M., Rooney, K., Lintzeris, N., Bruno, R., Booth, J., Arnold, J., McGregor, I. (2013). Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence, 133(2), 763-767. [More Information]
  • Spencer, J., Chohan, T., Karl, T., Arnold, J. (2013). Female neuregulin 1 heterozygous mice require repeated exposure to Δ9-tetrahydrocannabinol to alter sensorimotor gating function. Pharmacopsychiatry, 46(7), 286-291. [More Information]
  • Spencer, J., Darbyshire, K., Boucher, A., Kashem, M., Long, L., McGregor, I., Karl, T., Arnold, J. (2013). Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Frontiers in Cellular Neuroscience, 7, 1-13. [More Information]
  • Kassem, M., Lagopoulos, J., Stait-Gardner, T., Price, W., Chohan, T., Arnold, J., Hatton, S., Bennett, M. (2013). Stress-Induced Grey Matter Loss Determined by MRI Is Primarily Due to Loss of Dendrites and Their Synapses. Molecular Neurobiology, 47(2), 645-661. [More Information]
  • Long, L., Chesworth, R., Huang, X., McGregor, I., Arnold, J., Karl, T. (2013). Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. International Journal of Neuropsychopharmacology, 16(1), 163-175. [More Information]
  • Karl, T., Arnold, J. (2013). What does a mouse tell us about neuregulin 1-cannabis interactions? Frontiers in Cellular Neuroscience, 7, 1-4. [More Information]

2012

  • Spencer, J., Darbyshire, K., Boucher, A., Arnold, J. (2012). Adolescent neuregulin 1 heterozygous mice display enhanced behavioral sensitivity to methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 39(2), 376-381. [More Information]
  • Arnold, J., Hone, P., Holland, M., Allen, J. (2012). CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacological Reports, 64(3), 751-757. [More Information]
  • Long, L., Chesworth, R., Huang, X., Wong, A., Spiro, A., McGregor, I., Arnold, J., Karl, T. (2012). Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. PLoS One, 7(4), 1-11. [More Information]
  • Spiro, A., Wong, A., Boucher, A., Arnold, J. (2012). Enhanced Brain Disposition and Effects of triangle 9-Tetrahydrocannabinol in P-Glycoprotein and Breast Cancer Resistance Protein Knockout Mice. PLoS One, 7(4), 1-6. [More Information]
  • Wong, A., Gunasekaran, N., Hancock, D., Denyer, G., Meng, L., Radford, J., McGregor, I., Arnold, J. (2012). The major plant-derived cannabinoid 9-tetrahydrocannabinol promotes hypertrophy and macrophage infiltration in adipose tissue. Hormone And Metabolic Research, 44(2), 105-113. [More Information]
  • Chesworth, R., Yulyaningsih, E., Cappas, E., Arnold, J., Salis, A., Karl, T. (2012). The response of neuregulin 1 mutant mice to acute restraint stress. Neuroscience Letters, 515(1), 82-86. [More Information]
  • Karl, T., Cheng, D., Garner, B., Arnold, J. (2012). The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opinion on Therapeutic Targets, 16(4), 407-420. [More Information]
  • Arnold, J., Boucher, A., Karl, T. (2012). The Yin and Yang of Cannabis-induced Psychosis: the Actions of (D)(9)-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia. Current Pharmaceutical Design, 18(32), 5113-5130. [More Information]

2011

  • Bowen, M., Carson, D., Spiro, A., Arnold, J., McGregor, I. (2011). Adolescent Oxytocin Exposure Causes Persistent Reductions in Anxiety and Alcohol Consumption and Enhances Sociability in Rats. PLoS One, 6(11), 1 (e27237)-11. [More Information]
  • Klein, C., Karanges, E., Spiro, A., Wong, A., Spencer, J., Huynh, T., Gunasekaran, N., Karl, T., Long, L., Huang, X., Arnold, J., McGregor, I., et al (2011). Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology, 218(2), 443-457. [More Information]
  • Ferguson (Sokolic), L., Long, L., Hunt, G., Arnold, J., McGregor, I. (2011). Disruptive effects of the prototypical cannabinoid Delta9-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats. Behavioural Pharmacology, 22(3), 191-202. [More Information]
  • Boucher, A., Arnold, J., Hunt, G., Spiro, A., Spencer, J., Brown, C., McGregor, I., Bennett, M., Kassiou, M. (2011). Resilience and Reduced C-FOS Expression in P2X7 Receptor Knockout Mice Exposed to Repeated Forced Swim Test. Neuroscience, 189, 170-177. [More Information]
  • Boucher, A., Hunt, G., Micheau, J., Huang, X., McGregor, I., Karl, T., Arnold, J. (2011). The schizophrenia-susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology, 14(5), 631-643. [More Information]

2010

  • Long, L., Chesworth, R., Arnold, J., Karl, T. (2010). A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology, 211(3), 277-289. [More Information]
  • Arnold, J., Dielenberg, R., McGregor, I. (2010). Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: Strain differences in drug-induced anxiety. Life Sciences, 87(17-18), 572-578. [More Information]
  • van Nieuwenhuijzen, P., Long, L., Hunt, G., Arnold, J., McGregor, I. (2010). Residual social, memory and oxytocin-related changes in rats following repeated exposure to gamma-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Psychopharmacology, 212(4), 663-674. [More Information]
  • Carson, D., Hunt, G., Guastella, A., Barber, L., Cornish, J., Arnold, J., Boucher, A., McGregor, I. (2010). Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. Addiction Biology, 15(4), 448-463. [More Information]
  • Boucher, A., Hunt, G., Micheau, J., Huang, X., McGregor, I., Karl, T., Arnold, J. (2010). The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology, 14(5), 631-643. [More Information]

2009

  • Long, L., Chesworth, R., Huang, X., McGregor, I., Arnold, J., Karl, T. (2009). A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. International Journal of Neuropsychopharmacology, 13 (2010)(7), 861-876. [More Information]
  • Boucher, A., Vivier, L., Metna-Laurent, M., Brayda-Bruno, L., Mons, N., Arnold, J., Micheau, J. (2009). Chronic treatment with [DELTA]9-tetrahydrocannabinol impairs spatial memory and reduces zif268 expression in the mouse forebrain. Behavioural Pharmacology, 20(1), 45-55. [More Information]
  • Gunasekaran, N., Long, L., Dawson, B., Hansen, G., Richardson, D., Li, K., Arnold, J., McGregor, I. (2009). Reintoxication: the release of fat-stored delta-9-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. British Journal of Pharmacology, 158(5), 1330-1337. [More Information]

2008

  • Holland, M., Allen, J., Arnold, J. (2008). Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). European Journal of Pharmacology, 591, 128-131. [More Information]

2007

  • Quinn, H., Matsumoto, I., Callaghan, P., Long, L., Arnold, J., Gunasekaran, N., Thompson, M., Dawson, B., Mallet, P., Kashem, M., Matsuda-Matsumoto, H., Iwazaki, T., McGregor, I. (2007). Adolescent rats find repeated delta-9-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology, 33 (epub ahead of print Jun 20), 1-14. [More Information]
  • McGregor, I., Arnold, J. (2007). Cannabis reward: biased towards the fairer sex? British Journal of Pharmacology, 152(5), 562-564. [More Information]
  • Boucher, A., Arnold, J., Duffy, L., Schofield, P., Micheau, J., Karl, T. (2007). Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Δ9-tetrahydrocannabinol. Psychopharmacology, 192(3), 325-336. [More Information]
  • Boucher, A., Hunt, G., Karl, T., Micheau, J., McGregor, I., Arnold, J. (2007). Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience, 149(4), 861-870. [More Information]
  • Holland, M., Lau, D., Allen, J., Arnold, J. (2007). The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. British Journal of Pharmacology, 152(5), 815-824. [More Information]

2006

  • Karl, T., Duffy, L., Boucher, A., Arnold, J., Schofield, P. (2006). Genetic animal models for neuregulin 1 – valuable tools for schizophrenia research? Australian and New Zealand Journal of Psychiatry, 40(8, Supplement 2, Point No: O16), A115-A115.
  • Holland, M., Panetta, J., Hoskins, J., Bebawy, M., Roufogalis, B., Allen, J., Arnold, J. (2006). The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. Biochemical Pharmacology, 71(8), 1146-1154. [More Information]

2005

  • Holland, M., Allen, J., Bebawy, M., Roufogalis, B., Arnold, J. (2005). Cannabinoid Modulation of P-Glycoprtein Efflux Activity and Expression (Netherlands). Interantional association for cannabis as medicine conference, The Netherlands: Australian Society of Clinical and experimental Pharmacologists and Toxicologista.
  • Arnold, J., Holland, M., Bebawy, M., Roufogalis, B., Allen, J. (2005). Cannabinoid Modulation of P-Glycoprtein Efflux Activity and Expression (Spain). SOCIEDAD ESPANOLA DE INVESTIGACION SOBRE CANNABINOIDES, Barcelona: Australian Society of Clinical and experimental Pharmacologists and Toxicologista.
  • Morley, K., Arnold, J., McGregor, I. (2005). Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 29(5), 648-657. [More Information]
  • Arnold, J. (2005). The role of endocannabinoid transmission in cocaine addiction. Pharmacology, Biochemistry and Behavior, 81(2), 396-406. [More Information]

2001

  • Arnold, J., Hunt, G., McGregor, I. (2001). Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rat. Life Sciences, 70, 97-108.
  • Arnold, J., Topple, A., Hunt, G., McGregor, I., Mallet, P. (2001). The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Research, 921, 240-255.

To update your profile click here. For support on your academic profile contact .